Assignee
INNOVENT BIOLOGICS SUZHOU CO LTD
CN·18 granted patents·38 pending applications·21 citations·filing 2016–2023
Top patents by PatentIndex Score
56 records- 0186US11292836B2Anti-CD47 antibodies and uses thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2018·Granted Apr 5, 2022·3 cites·20 claims
- 0285US10316089B2PD-1 antibodiesINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2016·Granted Jun 11, 2019·7 cites·31 claims
- 0383US11274153B2Anti-PD-L1 nanobody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2017·Granted Mar 15, 2022·3 cites·11 claims
- 0479US11370837B2Anti-TIGIT antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2019·Granted Jun 28, 2022·2 cites·22 claims
- 0576US11512131B2Anti-PD-L1 antibody and uses thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2018·Granted Nov 29, 2022·1 cites·37 claims
- 0675US12098195B2Anti-IL-23p19 antibody and use thereof in treating diseasesINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2019·Granted Sep 24, 2024·1 cites·27 claims
- 0775US11732044B2Anti-LAG-3 antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2018·Granted Aug 22, 2023·1 cites·21 claims
- 0875US11485795B2Anti-PCSK9 antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2017·Granted Nov 1, 2022·1 cites·29 claims
- 0972US10913801B2PD-1 antibodiesINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2017·Granted Feb 9, 2021·1 cites·16 claims
- 1070US12269855B2Interleukin-2 and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2019·Granted Apr 8, 2025·1 cites·12 claims
- 1164US2026062490A1Mutant promoting homologous pairing of heavy and light chains of multispecific antibodyINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2023·Application pending·0 cites
- 1261US2025296973A1Treatment method using mazdutideINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2023·Application pending·0 cites
- 1359US2025034268A1Antibody binding to bcma and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 1457US2025002570A1Anti-vegf a and vegf c bispecific antibodies and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 1555US2024343799A1ANTI-CD79BxCD3 BISPECIFIC ANTIBODY AND USE THEREOFINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 1655US2025074996A1ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOFINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 1754US2024247057A1Bispecific binding molecule binding to vegf and ang2 and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 1854US2023391854A1Monoclonal antibody for coronavirus spike protein, and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 1954US2024293457A1Claudin18.2 chimeric antigen receptor and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 2054US2024026019A1Anti-tnfr2 antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 2153US2024293513A1Use of mazdutideINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 2252US2023235047A1Anti-claudin18.2 antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 2351US11708417B2Miniaturized antibody of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR), and polymer and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2019·Granted Jul 25, 2023·0 cites·25 claims
- 2451US2023312741A1Anti-cd73 antibody and uses thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 2550US2024101677A1Single-domain antibody against cd16a and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 2650US2024239881A1Anti-ang-2 antibody and its usageINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 2750US2022332846A1Use of anti-pcsk9 antibody in method for preventing or treating cholesterol-related diseaseINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 2850US2023357389A1Anti-claudin18.2 and cd3 bispecific antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 2949US2022112284A1Novel bispecific antibody molecule and bispecific antibody simultaneously binding to pd-l1 and lag-3INNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 3049US2023173069A1Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 3148US2023374132A1Anti-cd3 antibody and uses thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 3248US2024197833A1Oxm3 storage agent, oxm3 formulation and preparation methodINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 3348US2023056821A1Use of fusion protein in treatment of age-related macular degenerationINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 3447US11655296B2Anti-CD47 antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2019·Granted May 23, 2023·0 cites·19 claims
- 3547US11498972B2Anti-OX40 antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2018·Granted Nov 15, 2022·0 cites·24 claims
- 3647US2022259554A1Cell culture method and application thereof based on high-density and continuous inoculationINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 3746US11807663B2Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2019·Granted Nov 7, 2023·0 cites·19 claims
- 3846US2024228579A1Fc mutant with altered binding to fc receptorINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2022·Application pending·0 cites
- 3946US2023174604A1Interleukin-2 mutant and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 4046US2022062416A1Preparation comprising anti-pcsk9 antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2019·Application pending·0 cites
- 4145US2024034795A1Protein containing heterodimer antibody fc, and preparation method thereforINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 4245US2023080706A1Recombinant fully human anti-tigit monoclonal antibody formulation, method for preparing same and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 4345US2023287124A1Pd-l1/lag-3 bispecific antibody formulation and preparation method therefor and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 4444US2024043487A1Interleukin-21 mutant and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 4543US12551531B2Interleukin-2 and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2019·Granted Feb 17, 2026·0 cites·13 claims
- 4643US2023145766A1Interleukin-2 mutant and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2021·Application pending·0 cites
- 4743US2023257374A1Novel kras g12c protein inhibitor, preparation method therefor, and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2020·Application pending·0 cites
- 4842US11130809B2PD-1 antibody formulationINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2017·Granted Sep 28, 2021·0 cites·14 claims
- 4942US10597454B2PD-1 antibodiesINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2016·Granted Mar 24, 2020·0 cites·20 claims
- 5042US2022127364A1Novel anti-pd-l1 antibody and uses thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2020·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when INNOVENT BIOLOGICS SUZHOU CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →